JournalTOCs

BioCentury Innovations
Number of Followers: 2

Full-text available via subscription

Subscription journal
ISSN (Online) 2377-3030
Published by BioCentury

[1 journal]

Advisory panels need to be reformed — but not by barring industry
voices: a Perspective
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 18, 2025 4:31 PM PDT BIOCENTURY EDITOR'S COMMENTARYADVISORY PANELS NEED TO BE REFORMED — BUT NOT BY BARRING INDUSTRY VOICES: A PERSPECTIVEBY The new FDA commissioner’s push to remove industry reps won’t get far, but it could further erode public trust https://www.biocentury.com/article/655684/advisory-panels-need-to-be-reformed-but-not-by-barring-industry-voices-a-perspective© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 18 Apr 2025 16:31:11 -070
Science Spotlight: Ultrasound-controlled CAR T cells
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 18, 2025 3:57 PM PDT BIOCENTURY DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: ULTRASOUND-CONTROLLED CAR T CELLSBY BioCentury’s roundup of translational innovations also includes a protein conjugation strategy, a SMURF1 inhibitor for hypertension, and morehttps://www.biocentury.com/article/655642/science-spotlight-ultrasound-controlled-car-t-cells© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 18 Apr 2025 15:57:05 -070
Biotech sees a new, hard era ahead, survey finds
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 18, 2025 3:37 PM PDT BIOCENTURY POLITICS, POLICY & LAWBIOTECH SEES A NEW, HARD ERA AHEAD, SURVEY FINDSBY Biotech is reeling, fearful and furious about the fallout of tariffs, FDA and NIH policies, says BioCentury’s Risk Sentiment surveyhttps://www.biocentury.com/article/655673/biotech-sees-a-new-hard-era-ahead-survey-finds© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 18 Apr 2025 15:37:37 -070
New fund Alis offers struggling biotechs an off-ramp: Finance Report
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 18, 2025 1:41 PM PDT BIOCENTURY FINANCENEW FUND ALIS OFFERS STRUGGLING BIOTECHS AN OFF-RAMP: FINANCE REPORTBY Plus: Updates from Glycomine, Attovia, Thirtyfivebio, Heparegenix, Duality, Pelthos and Third Harmonichttps://www.biocentury.com/article/655663/new-fund-alis-offers-struggling-biotechs-an-off-ramp-finance-report© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 18 Apr 2025 13:41:17 -070
Makary: New ultrarare path will provide approval based on ‘plausible
mechanism’
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 18, 2025 1:25 PM PDT BIOCENTURY REGULATIONMAKARY: NEW ULTRARARE PATH WILL PROVIDE APPROVAL BASED ON ‘PLAUSIBLE MECHANISM’BY FDA commissioner says pathway will offer ‘conditional’ approval in very rare diseaseshttps://www.biocentury.com/article/655680/makary-new-ultrarare-path-will-provide-approval-based-on-plausible-mechanism© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 18 Apr 2025 13:25:46 -070
Alzheimer’s research pulled into political crossfire as NIH cuts
accelerate
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 17, 2025 5:24 PM PDT BIOCENTURY DISCOVERY & TRANSLATIONALZHEIMER’S RESEARCH PULLED INTO POLITICAL CROSSFIRE AS NIH CUTS ACCELERATEBY Joins list of NIH-funded projects disrupted by terminations, freezeshttps://www.biocentury.com/article/655667/alzheimer-s-research-pulled-into-political-crossfire-as-nih-cuts-accelerate© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 17 Apr 2025 17:24:04 -070
Speed of China’s early clinical trials raises bar for Western
biotechs
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 17, 2025 4:19 PM PDT BIOCENTURY PRODUCT DEVELOPMENTSPEED OF CHINA’S EARLY CLINICAL TRIALS RAISES BAR FOR WESTERN BIOTECHS BY Faster recruitment is the biggest factor, but it’s not the only driver of China’s new edgehttps://www.biocentury.com/article/655627/speed-of-china-s-early-clinical-trials-raises-bar-for-western-biotechs© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 17 Apr 2025 16:19:33 -070
Executive order creates scramble to get pill penalty fix in reconciliation
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 17, 2025 3:53 PM PDT BIOCENTURY POLITICS, POLICY & LAWEXECUTIVE ORDER CREATES SCRAMBLE TO GET PILL PENALTY FIX IN RECONCILIATIONBY Trump wants to eliminate the pill penalty — but he isn’t saying how. That presents challenges for industry https://www.biocentury.com/article/655664/executive-order-creates-scramble-to-get-pill-penalty-fix-in-reconciliation© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 17 Apr 2025 15:53:04 -070
City Therapeutics adds to C-suite
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 17, 2025 3:52 PM PDT BIOCENTURY MANAGEMENT TRACKSCITY THERAPEUTICS ADDS TO C-SUITEBY Plus: Updates from EnPlusOne, Design, Werewolf, Ardelyx and Aim Vaccinehttps://www.biocentury.com/article/655661/city-therapeutics-adds-to-c-suite© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 17 Apr 2025 15:52:39 -070
U.S. risks ceding biotech to China, commission warns
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 16, 2025 6:11 PM PDT BIOCENTURY POLITICS, POLICY & LAWU.S. RISKS CEDING BIOTECH TO CHINA, COMMISSION WARNS BY National Security Commission on Emerging Biotechnology calls for bolstering U.S. industry, slowing China’s progresshttps://www.biocentury.com/article/655654/u-s-risks-ceding-biotech-to-china-commission-warns© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Wed, 16 Apr 2025 18:11:57 -070
Makary filling key FDA posts with policy veterans
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 16, 2025 5:30 PM PDT BIOCENTURY POLITICS, POLICY & LAWMAKARY FILLING KEY FDA POSTS WITH POLICY VETERANSBY Capitol Hill alum Grace Graham, Washington lawyer Lowell Zeta joining Office of the Commissionerhttps://www.biocentury.com/article/655656/makary-filling-key-fda-posts-with-policy-veterans© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Wed, 16 Apr 2025 17:30:59 -070
More C-suite changes at Dyne
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 16, 2025 3:20 PM PDT BIOCENTURY MANAGEMENT TRACKSMORE C-SUITE CHANGES AT DYNEBY Plus updates from Airna, Madrigal, Protara, Prologue, Alkermes and BioInnovation Institutehttps://www.biocentury.com/article/655647/more-c-suite-changes-at-dyne© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Wed, 16 Apr 2025 15:20:49 -070
Slow quarter for company creation in 1Q25, but megarounds persist
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 16, 2025 3:18 PM PDT BIOCENTURY DATA BYTESLOW QUARTER FOR COMPANY CREATION IN 1Q25, BUT MEGAROUNDS PERSISTBY Pace of seed/series A fundings down compared with past 1Qs, yet series of nine-digit investments pushed mean round size to new highhttps://www.biocentury.com/article/655649/slow-quarter-for-company-creation-in-1q25-but-megarounds-persist© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Wed, 16 Apr 2025 15:18:37 -070
Trump signals support for ending ‘pill penalty,’ hints at
reference pricing
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 15, 2025 6:22 PM PDT BIOCENTURY POLITICS, POLICY & LAWTRUMP SIGNALS SUPPORT FOR ENDING ‘PILL PENALTY,’ HINTS AT REFERENCE PRICINGBY Executive order includes steps to facilitate biosimilar and generic competition, drug importation, PBM transparencyhttps://www.biocentury.com/article/655639/trump-signals-support-for-ending-pill-penalty-hints-at-reference-pricing© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 15 Apr 2025 18:22:20 -070
Days after Hong Kong tumbles, ADC play Duality braves IPO
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 15, 2025 6:12 PM PDT BIOCENTURY DATA BYTEDAYS AFTER HONG KONG TUMBLES, ADC PLAY DUALITY BRAVES IPOBY Shanghai biotech’s shares double in debuthttps://www.biocentury.com/article/655632/days-after-hong-kong-tumbles-adc-play-duality-braves-ipo© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 15 Apr 2025 18:12:06 -070
In wake of Anthos buyout, CFO McIntyre joins Inhibikase
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 15, 2025 6:06 PM PDT BIOCENTURY MANAGEMENT TRACKSIN WAKE OF ANTHOS BUYOUT, CFO MCINTYRE JOINS INHIBIKASEBY BioCentury’s Management Roundup also includes updates from Galapagos, Proqr, GC, Gates MRI, Viatris and AB Sciexhttps://www.biocentury.com/article/655619/in-wake-of-anthos-buyout-cfo-mcintyre-joins-inhibikase© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 15 Apr 2025 18:06:51 -070
Drug companies’ playbook for deflecting tariffs
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 15, 2025 3:19 PM PDT BIOCENTURY POLITICS, POLICY & LAWDRUG COMPANIES’ PLAYBOOK FOR DEFLECTING TARIFFSBY To avoid sweeping tariffs, pharmas announce U.S. manufacturing investments, warn of generics shortageshttps://www.biocentury.com/article/655634/drug-companies-playbook-for-deflecting-tariffs© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 15 Apr 2025 15:19:49 -070
Verve impresses investors with second shot at PCSK9
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 15, 2025 3:10 PM PDT BIOCENTURY PRODUCT DEVELOPMENTVERVE IMPRESSES INVESTORS WITH SECOND SHOT AT PCSK9BY In BioCentury’s Clinical Report, Pfizer and BMS miss out on market opportunities, and morehttps://www.biocentury.com/article/655631/verve-impresses-investors-with-second-shot-at-pcsk9© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 15 Apr 2025 15:10:27 -070
Slow season for biopharma M&A amid stormy markets: Deals Report
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 14, 2025 7:24 PM PDT BIOCENTURY DEALSSLOW SEASON FOR BIOPHARMA M&A AMID STORMY MARKETS: DEALS REPORTBY Uncertainty in markets may be quashing appetite to complete transactionshttps://www.biocentury.com/article/655621/slow-season-for-biopharma-m-a-amid-stormy-markets-deals-report© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Mon, 14 Apr 2025 19:24:38 -070
Replacing animal models. Plus: RFK Jr. & FDA — a BioCentury
podcast
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 14, 2025 7:15 PM PDT BIOCENTURY PRODUCT DEVELOPMENTREPLACING ANIMAL MODELS. PLUS: RFK JR. & FDA — A BIOCENTURY PODCASTBY Assessing FDA’s plan to move away from animal toxicity testing. Crisis at FDA, NIH worsens. Biotech stock whirlwind.https://www.biocentury.com/article/655622/replacing-animal-models-plus-rfk-jr-fda-a-biocentury-podcast© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Mon, 14 Apr 2025 19:15:37 -070
Reduced animal testing could unlock host of benefits, but not overnight
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 14, 2025 6:11 PM PDT BIOCENTURY PRODUCT DEVELOPMENTREDUCED ANIMAL TESTING COULD UNLOCK HOST OF BENEFITS, BUT NOT OVERNIGHTBY FDA outlines three-year road map to reduce animal safety studies for mAbshttps://www.biocentury.com/article/655610/reduced-animal-testing-could-unlock-host-of-benefits-but-not-overnight© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Mon, 14 Apr 2025 18:11:55 -070
Freya: Restoring microbial balance in the reproductive tract
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 11, 2025 4:24 PM PDT BIOCENTURY EMERGING COMPANY PROFILEFREYA: RESTORING MICROBIAL BALANCE IN THE REPRODUCTIVE TRACTBY Shifting the inflammatory vaginal microbiome back to a healthy, https://www.biocentury.com/article/655590/freya-restoring-microbial-balance-in-the-reproductive-tract© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 11 Apr 2025 16:24:02 -070
Biopharma indexes rally to end white-knuckle week
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 11, 2025 4:21 PM PDT BIOCENTURY DATA BYTEBIOPHARMA INDEXES RALLY TO END WHITE-KNUCKLE WEEKBY After series of tariff announcements continued to roil markets, Friday’s gains returned the XBI and NBI nearly to midweek highshttps://www.biocentury.com/article/655615/biopharma-indexes-rally-to-end-white-knuckle-week© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 11 Apr 2025 16:21:41 -070
Kennedy’s remarks intensify FDA morale crisis
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 11, 2025 3:22 PM PDT BIOCENTURY REGULATIONKENNEDY’S REMARKS INTENSIFY FDA MORALE CRISISBY The HHS Secretary accused FDA of being corrupt, endorsed conspiracy theories, dismaying agency employeeshttps://www.biocentury.com/article/655612/kennedy-s-remarks-intensify-fda-morale-crisis© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 11 Apr 2025 15:22:30 -070
Preminger leaving J&J Innovation
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 11, 2025 3:08 PM PDT BIOCENTURY MANAGEMENT TRACKSPREMINGER LEAVING J&J INNOVATIONBY Plus: Management changes at Kymera, Arcutis and Merakrishttps://www.biocentury.com/article/655609/preminger-leaving-j-j-innovation© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 11 Apr 2025 15:08:17 -070
Incubated at Third Rock, Merida moves Fc therapies toward clinic with
$121M: Finance Report
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 11, 2025 2:57 PM PDT BIOCENTURY FINANCEINCUBATED AT THIRD ROCK, MERIDA MOVES FC THERAPIES TOWARD CLINIC WITH $121M: FINANCE REPORTBY Plus: Caris, Raythera, Immunitybio among those raising cashhttps://www.biocentury.com/article/655607/incubated-at-third-rock-merida-moves-fc-therapies-toward-clinic-with-121m-finance-report© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 11 Apr 2025 14:57:59 -070
The sky is not falling, yet: a Perspective
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 11, 2025 1:47 PM PDT BIOCENTURY EDITOR'S COMMENTARYTHE SKY IS NOT FALLING, YET: A PERSPECTIVEBY Despite the rumors, biotech’s specialist investors aren’t at crisis pointhttps://www.biocentury.com/article/655605/the-sky-is-not-falling-yet-a-perspective© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 11 Apr 2025 13:47:38 -070
Base editor efficiency boom. China leading charge'
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 11, 2025 10:53 AM PDT BIOCENTURY DISCOVERY & TRANSLATIONBASE EDITOR EFFICIENCY BOOM. CHINA LEADING CHARGE'BY Recently published studies reveal advances in precision and performance, driven largely by labs in Chinahttps://www.biocentury.com/article/655583/base-editor-efficiency-boom-china-leading-charge© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 11 Apr 2025 10:53:14 -070
New CEOs at Alterome, Valo and Imbria
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 10, 2025 3:44 PM PDT BIOCENTURY MANAGEMENT TRACKSNEW CEOS AT ALTEROME, VALO AND IMBRIABY Plus: Updates from Harbour BioMed, Ottimo and NeOnchttps://www.biocentury.com/article/655594/new-ceos-at-alterome-valo-and-imbria© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 10 Apr 2025 15:44:24 -070
Biotech stocks resume tumble
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 10, 2025 3:35 PM PDT BIOCENTURY DATA BYTEBIOTECH STOCKS RESUME TUMBLEBY Sector leads broader market down as tariff worries persisthttps://www.biocentury.com/article/655596/biotech-stocks-resume-tumble© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 10 Apr 2025 15:35:00 -070
As more NIH cuts loom, researchers warn U.S. science at risk
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 10, 2025 11:58 AM PDT BIOCENTURY POLITICS, POLICY & LAWAS MORE NIH CUTS LOOM, RESEARCHERS WARN U.S. SCIENCE AT RISKBY In addition to obvious blows, unseen damage could be lasting, NIH staff caution https://www.biocentury.com/article/655599/as-more-nih-cuts-loom-researchers-warn-u-s-science-at-risk© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 10 Apr 2025 11:58:04 -070
Kennedy uses pseudo-science to justify holding up vaccine approval
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 10, 2025 8:37 AM PDT BIOCENTURY POLITICS, POLICY & LAWKENNEDY USES PSEUDO-SCIENCE TO JUSTIFY HOLDING UP VACCINE APPROVALBY HHS Secretary Kennedy inaccurately said single-antigen vaccines don’t protect against respiratory diseaseshttps://www.biocentury.com/article/655591/kennedy-uses-pseudo-science-to-justify-holding-up-vaccine-approval© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Thu, 10 Apr 2025 08:37:55 -070
Early pains, late gains for biopharmas on Wall Street
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 09, 2025 2:56 PM PDT BIOCENTURY DATA BYTEEARLY PAINS, LATE GAINS FOR BIOPHARMAS ON WALL STREETBY Biotech and pharma indexes reacted to a pair of signals from the White House on tariffs, resulting in a drastic turnaroundhttps://www.biocentury.com/article/655587/early-pains-late-gains-for-biopharmas-on-wall-street© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Wed, 09 Apr 2025 14:56:23 -070
VC coffers still full as bear market returns
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 09, 2025 1:35 PM PDT BIOCENTURY DATA BYTEVC COFFERS STILL FULL AS BEAR MARKET RETURNSBY Twenty of the most active VCs raised more than $32.5B in last four yearshttps://www.biocentury.com/article/655585/vc-coffers-still-full-as-bear-market-returns© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Wed, 09 Apr 2025 13:35:53 -070
Cartesian's autoimmune CAR T looks durable, Arvinas’ LRRK2 data, and
more: Clinical Report
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 08, 2025 5:11 PM PDT BIOCENTURY PRODUCT DEVELOPMENTCARTESIAN'S AUTOIMMUNE CAR T LOOKS DURABLE, ARVINAS’ LRRK2 DATA, AND MORE: CLINICAL REPORTBY The week’s gainers and decliners after data readouts xhttps://www.biocentury.com/article/655577/cartesian-s-autoimmune-car-t-looks-durable-arvinas-lrrk2-data-and-more-clinical-report© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 08 Apr 2025 17:11:04 -070
As Rocket awaits FDA review, J&J vet Chaudhuri joins as commercial
lead
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 08, 2025 5:08 PM PDT BIOCENTURY MANAGEMENT TRACKSAS ROCKET AWAITS FDA REVIEW, J&J VET CHAUDHURI JOINS AS COMMERCIAL LEADBY Plus: C-suite changes at Freenome, Telix, Trex Bio, Myricx, General Oncology, Bostongene and Acrivonhttps://www.biocentury.com/article/655574/as-rocket-awaits-fda-review-j-j-vet-chaudhuri-joins-as-commercial-lead© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 08 Apr 2025 17:08:45 -070
Another bleak day for stocks
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 08, 2025 5:03 PM PDT BIOCENTURY DATA BYTEANOTHER BLEAK DAY FOR STOCKSBY XBI and NBI continue to fall more than broader marketshttps://www.biocentury.com/article/655581/another-bleak-day-for-stocks© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 08 Apr 2025 17:03:29 -070
VEGF multispecifics get innovative at AACR 2025
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 08, 2025 2:34 PM PDT BIOCENTURY PRODUCT DEVELOPMENTVEGF MULTISPECIFICS GET INNOVATIVE AT AACR 2025BY New binding domains, target combinations and molecule structures define the VEGF multispecifics to be presented at AACR 2025https://www.biocentury.com/article/655518/vegf-multispecifics-get-innovative-at-aacr-2025© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 08 Apr 2025 14:34:53 -070
The expanding pipeline of VEGF multispecifics
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 08, 2025 1:46 PM PDT BIOCENTURY DATA BYTETHE EXPANDING PIPELINE OF VEGF MULTISPECIFICSBY At least 35 VEGF multispecific programs are in developmenthttps://www.biocentury.com/article/655575/the-expanding-pipeline-of-vegf-multispecifics© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Tue, 08 Apr 2025 13:46:16 -070
FDA shakeup, tariffs fallout, and an AACR preview: a BioCentury podcast
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 07, 2025 4:10 PM PDT BIOCENTURY POLITICS, POLICY & LAWFDA SHAKEUP, TARIFFS FALLOUT, AND AN AACR PREVIEW: A BIOCENTURY PODCASTBY How chaos at the U.S. regulator and a trade war are creating new uncertainties for biotech and investorshttps://www.biocentury.com/article/655566/fda-shakeup-tariffs-fallout-and-an-aacr-preview-a-biocentury-podcast© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Mon, 07 Apr 2025 16:10:14 -070
Latest capsid deal gives a lifeline to Sangamo: Deals Report
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 07, 2025 4:05 PM PDT BIOCENTURY DEALSLATEST CAPSID DEAL GIVES A LIFELINE TO SANGAMO: DEALS REPORTBY Plus: Sanofi gains license to another Nurix program; Allakos takes Tang/Concentra buyout offerhttps://www.biocentury.com/article/655562/latest-capsid-deal-gives-a-lifeline-to-sangamo-deals-report© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Mon, 07 Apr 2025 16:05:53 -070
Hong Kong stocks plunge. More tariffs loom
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 07, 2025 4:02 PM PDT BIOCENTURY DATA BYTEHONG KONG STOCKS PLUNGE. MORE TARIFFS LOOMBY Previously a bright spot in 2025 markets, Hong Kong stocks take a sharp downturnhttps://www.biocentury.com/article/655570/hong-kong-stocks-plunge-more-tariffs-loom© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Mon, 07 Apr 2025 16:02:43 -070
Hodits joining Angelini venture unit
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 07, 2025 3:20 PM PDT BIOCENTURY MANAGEMENT TRACKSHODITS JOINING ANGELINI VENTURE UNITBY Plus: Zenas taps Tesaro vet Lakin for CSO job; Lift hires Exleyhttps://www.biocentury.com/article/655558/hodits-joining-angelini-venture-unit© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Mon, 07 Apr 2025 15:20:18 -070
Modest proposals for promoting ‘radical transparency’
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 07, 2025 3:05 PM PDT BIOCENTURY EDITOR'S COMMENTARYMODEST PROPOSALS FOR PROMOTING ‘RADICAL TRANSPARENCY’BY In an Editor’s Commentary, Washington Editor Steve Usdin explains how RFK Jr., Bhattacharya and Makary can fulfill their promises https://www.biocentury.com/article/655537/modest-proposals-for-promoting-radical-transparency© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Mon, 07 Apr 2025 15:05:47 -070
Former FDA officials call HHS plan for agency ‘nonsensical,’
unworkable
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 07, 2025 7:15 AM PDT BIOCENTURY POLITICS, POLICY & LAWFORMER FDA OFFICIALS CALL HHS PLAN FOR AGENCY ‘NONSENSICAL,’ UNWORKABLEBY HHS has circulated an outline for reorganizing FDAhttps://www.biocentury.com/article/655559/former-fda-officials-call-hhs-plan-for-agency-nonsensical-unworkable© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Mon, 07 Apr 2025 07:15:37 -070
Tariffs are here — sweating the SWOT analysis, a letter from the
Editor
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 04, 2025 5:53 PM PDT BIOCENTURY EDITOR'S COMMENTARYTARIFFS ARE HERE — SWEATING THE SWOT ANALYSIS, A LETTER FROM THE EDITORBY Managing through the crisis: assume no favors and plan conservativelyhttps://www.biocentury.com/article/655554/tariffs-are-here-sweating-the-swot-analysis-a-letter-from-the-editor© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 04 Apr 2025 17:53:11 -070
Makary facing key test: a Perspective
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 04, 2025 5:41 PM PDT BIOCENTURY EDITOR'S COMMENTARYMAKARY FACING KEY TEST: A PERSPECTIVEBY The FDA commissioner must swiftly reverse decision to conduct a political review of a COVID vaccine — or risk irreparablehttps://www.biocentury.com/article/655541/makary-facing-key-test-a-perspective© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 04 Apr 2025 17:41:04 -070
XBI tumbles as ‘Wall of Worry’ takes hold of biotech
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 04, 2025 5:27 PM PDT BIOCENTURY DATA BYTEXBI TUMBLES AS ‘WALL OF WORRY’ TAKES HOLD OF BIOTECHBY Key biotech ETF has fallen nearly 30% since November peak, as FDA turmoil, tariffs weigh on industryhttps://www.biocentury.com/article/655545/xbi-tumbles-as-wall-of-worry-takes-hold-of-biotech© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 04 Apr 2025 17:27:49 -070
Science Spotlight: A FOXP3 regulator to enhance induced Tregs
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 04, 2025 5:26 PM PDT BIOCENTURY DISCOVERY & TRANSLATIONSCIENCE SPOTLIGHT: A FOXP3 REGULATOR TO ENHANCE INDUCED TREGSBY BioCentury’s roundup of translational innovations also includes insights into high-fat diet disruption of feeding motivation; ER-targeted antigens; and morehttps://www.biocentury.com/article/655532/science-spotlight-a-foxp3-regulator-to-enhance-induced-tregs© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 04 Apr 2025 17:26:29 -070
Bearing down in a turbulent market
- Free pre-print version: Loading...
  Rate this result: What is this?
  
  Please help us test our new pre-print finding feature by giving the pre-print link a rating.
  A 5 star rating indicates the linked pre-print has the exact same content as the published article.
  
  Abstract: APR 04, 2025 4:07 PM PDT BIOCENTURY FINANCEBEARING DOWN IN A TURBULENT MARKETBY BioCentury’s 2Q25 financial markets previewhttps://www.biocentury.com/article/655536/bearing-down-in-a-turbulent-market© 2025 BioCentury Inc. All Rights Reserved
  PubDate: Fri, 04 Apr 2025 16:07:06 -070

HOME > Browse the 73 Subjects covered by JournalTOCs
Subject	Total Journals